Physician profile
Jorge E Ribet
NPI 1245335215
$1,801.11
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $383 · 2020: $456 · 2021: $274 · 2022: $65.25 · 2023: $428 · 2024: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $622.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $583.93 | 2019-2024 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $297.73 | 2020-2024 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $178.99 | 2019-2024 | Jardiance |
| Pfizer INC. | $149.18 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $123.93 | 2020-2023 | Xarelto |
| Glaxosmithkline, LLC. | $104.38 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.29 | 2023-2024 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $58.39 | 2021 | |
| Amarin Pharma, INC. | $53.17 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $44.25 | 2019-2023 | |
| Amgen INC. | $31.55 | 2022-2023 | Otezla, Repatha |
| Medtronic, INC. | $22.41 | 2023 | Vanta Adaptivestim |
| Abbott Laboratories | $17.26 | 2023 | Proclaim |
| E.R. Squibb & Sons, L.L.C. | $14.72 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.39 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $13.33 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Ribet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.